Filter
357
Text search:
Pre-exposure
Prophylaxis
Featured
53
95
Language
Document type
168
95
49
16
14
7
3
2
1
1
Countries / Regions
17
14
13
10
9
8
7
5
4
4
4
4
4
3
3
3
3
3
3
3
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
113
27
18
9
5
Toolboxes
183
12
10
7
5
5
4
4
3
3
2
2
2
1
1
1
1
This document aims to provide Ministry of Health guidance on the implementation of PEP and PrEP to prevent HIV transmission and improve overall health outcomes. This comprehensive approach reflects the commitment of all involved in combating HIV and enhancing public health.
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk
...
This technical brief aims to support these trends, accelerated by the COVID-19 pandemic, and improve PrEP uptake, persistence, and effective use by providing implementation guidance for differentiated and simplified service delivery. The brief aims to support a range of stakeholders in planning and
...
Evidence shows that oral pre-exposure prophylaxis (PrEP) reduces the risk of contracting HIV during sexual intercourse by more than 90% when take
...
Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV prevention o
...
Esc Anna Nery 2024;28:e20240093
This PrEP Implementation SOP will serve as a more detailed guide for NCHADS, partners and providers at FHC, NGO clinics and medically supervised CBO DICs
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex B
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex C
Modelling shows that it will be essential to complement lenacapavir with additional prevention options, testing and treatment. See “Meeting reports” at https://www.unaids.org/en/resources/publications/all for a description of models and tools to estimate potential impact and quantifications requ
...
The Lancet HIV. Volume 12, Issue 10e712-e721October 2025. This article from The Lancet HIV estimates the impact of the PEPFAR funding pause for PrEP on HIV infections in sub-Saharan Africa.
The new WHO recommendations for rabies immunization supersede the 2010 WHO position
on pre-exposure prophylaxis (PrEP) and post-exposure
...
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex D
Mathematical modelling of lenacapavir: landscaping review on impact and cost–effectiveness
recommended
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex E
Guidelines on lenacapavir for HIV prevention and testing strategies for long-acting injectable pre-exposure prophylaxis. Web Annex F
